U.S. Markets closed

BioCardia, Inc. (BCDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.35000.0000 (0.00%)
At close: 12:59PM EST
Sign in to post a message.
  • A
    Andrew
    How does a company trading at about $3/share do a secondary offering @ $2.10/share? I think it may be clear:
    - 75% of stock is held by Insiders
    - so, "family and friends" get to buy in at $2.10, well below intrinsic vale - look at the pipeline and stages.
    Owners - largely insiders - will get (even more) wealthy as we move up from here. I think a lot of selling had to do with negative reaction of non-insider) shareholders, who have a right to be disillusioned.
    But -> If you're getting in under $3, this is a great investment, short and long-term.
  • A
    Andrew
    I realize noone reads this thread, but in any event - is the investment "community" awatr of this Study???
    "In March 2020, the Data Safety Monitoring Board indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. To date, 75 patients have been enrolled at 25 active centers. The trial is sponsored, in part, by the Maryland Stem Cell Research Foundation and has reimbursement from the Centers for Medicare and Medicaid Services (CMS)."

    https://www.biospace.com/article/releases/biocardia-announces-cardiamp-heart-failure-pivotal-trial-continues-with-first-patient-randomized-in-covid-19-era/
  • L
    Lou
    This is still a fairly unknown stock; with a little coverage and volume I think we will see significant gains soon.
    Bullish
  • B
    BioClinicalRS
    Cardiac catheterization is in my field. BCDA has built a strong history of solid FDA approved products that build upon one another to offer stem cell regeneration of heart tissue. The remaining clinical trials, I expect, will produce the same outcome. No adverse events and clear clinical improvement. All the major heart centers are on the trial, including Mayo, NY, Cedar Sinai, Cornell, etc. With heart disease as the #1 killer, I’ll gladly buy your shares.
  • B
    BioClinicalRS
    No small thing earlier this month. Henry Ford, Cedar Sinai, Texas A&M and more great institutions onboard with study that’s doing great. Plus a patent in three countries to assay the efficacy upfront. Nothing but greatness here.

    https://finance.yahoo.com/news/biocardia-announces-u-patent-covering-130010813.html
  • L
    Lou
    Initiated by Brookline Capital Management with a price target of $22.00 on 11/26/2019!!
  • L
    Lou
    510(k) Premarket Notification
    www.accessdata.fda.gov
  • D
    David
    now a 9 to 1 reverse split
  • A
    Alex
    I think I am getting in here. Had a nice drop after the offering. Seems normal, but other than that.... things look good here?
    Bullish
  • A
    Andrew
    Flying Under the Radar...
    "COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Exploration
    The Company also intends to submit an IND for the use of its NK1R+ MSC delivered via intravenous (IV) infusion for Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.
    Based on preliminary clinical reports on COVID-19, respiratory failure complicated by ARDs is the leading cause of death for COVID-19 patients.1 ARDS is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs.
    The anti-inflammatory effects of MSC have been well-documented and MSC have been shown to reduce inflammation and injury in models of lung disease.2 The specific MSCs used in BioCardia’s allogenic cell therapy are expanded from cells selected for the presence of the NK1 receptor, which is known to bind to substance P, an important neuropeptide associated with inflammation throughout the body and a primary mediator of inflammation in the airways."
  • B
    BioClinicalRS
    Waiting for next earnings with their Helix Catheter on the market and CardiAMP study updates from the most prestigious medical centers in the US.
    Bullish
  • t
    trust_ur_instinct
    I feel for all longs here. RS is admission of failure by management and gift for shorties who will hammer it down to its pre-split price or even lower, sadly.
  • j
    jp_whistledick_iii
    Taking off again, looking good, real good.
  • L
    Lou
    FDA approval today??? Trading halted current bid over $6.00!!
  • 2
    2Invest
    i just sold mine ... its going to be a rough time ahead here but i will sleep well 😴
  • 2
    2Invest
    i got out just in time, its going down the hill from now ...
  • J
    Jerry
    What happened to this company?
  • c
    chris
    Any ideas why there is relatively no movement?
  • A
    Andrew
    In the past year, management and insiders have Acquired (no Dispositions) considerable stock between $3 - $6/share. Much as recently as Q2:

    https://eresearch.fidelity.com/eresearch/evaluate/fundamentals/ownership.jhtml?stockspage=insidertransactions&sortBy=TotalHoldings&sortDir=d&symbols=BCDA&timeFrame=1&showPriceLine=no
    Institutional and mutual fund ownership summary for BIOCARDIA INC (BCDA)
    Institutional and mutual fund ownership summary for BIOCARDIA INC (BCDA)
    eresearch.fidelity.com
  • S
    SinghisKing
    Could be a multi bagger Dr. Frost bought a huge chunck